What is the difference between AOD-9604 and Semaglutide?

AOD-9604: AOD-9604 is a 16-amino-acid synthetic peptide corresponding to the C-terminal fragment of human growth hormone (residues 177-191) with an additional N-terminal tyrosine. Developed by Metabolic Pharmac... Semaglutide: Semaglutide is an FDA-approved GLP-1 receptor agonist marketed as Ozempic (SubQ, type 2 diabetes), Wegovy (SubQ, chronic weight management and cardiovascular risk reduction in obesity), and Rybelsus (...

AOD-9604 vs Semaglutide

Q: Can you stack AOD-9604 and Semaglutide?

AOD-9604 (metabolic) and Semaglutide (metabolic) are in the same category and may have overlapping mechanisms — researchers should review both profiles carefully before combining. Consult a licensed provider before combining any compounds.

Head-to-head comparison of AOD-9604 and Semaglutide — mechanism, dosing, side effects, legal status, and pricing.

AOD-9604

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to the C-terminal fragment of human growth hormone (residues 177-191) with an additional N-terminal tyrosine. Developed by Metabolic Pharmaceuticals (Australia) to isolate a purported 'lipolytic' activity of GH without GH-receptor-mediated growth or diabetogenic effects. AOD-9604 is NOT FDA-approved for any indication; controlled human trials for obesity did not demonstrate clinically meaningful weight loss, and obesity development was terminated in 2007.

Profile Prices Calculator

Semaglutide

Semaglutide is an FDA-approved GLP-1 receptor agonist marketed as Ozempic (SubQ, type 2 diabetes), Wegovy (SubQ, chronic weight management and cardiovascular risk reduction in obesity), and Rybelsus (oral, type 2 diabetes). It is a synthetic analog of native GLP-1 with a fatty-acid (C18 diacid) side chain that enables albumin binding, giving it a ~165-hour half-life suitable for once-weekly injection.

Profile Prices Calculator

AOD-9604

Semaglutide

Category

Metabolic

Legal Status

Research Only

FDA Approved

Mechanism

The original preclinical hypothesis was that hGH(177-191) retains a lipolytic activity via a non-GH-receptor pathway, with some rodent data implicating β3-adrenoceptor expression and cAMP signaling in adipocytes. This mechanism is disputed and has not been robustly reproduced in controlled human studies — Phase 2 trials showed no significant effect on body weight versus placebo. AOD-9604 does not measurably raise serum IGF-1 and does not impair glucose tolerance in human safety studies, which is consistent with lack of GH-receptor agonism but does not establish clinical lipolytic efficacy.

Semaglutide is a long-acting GLP-1 receptor agonist. Binding the GLP-1 receptor enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release, and slows gastric emptying. It also acts on hypothalamic appetite centers to reduce hunger and caloric intake, driving substantial weight loss in addition to glycemic improvement.

Dose Range

250–500 mcg

Wegovy (obesity): 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg SubQ weekly. Ozempic (T2DM): 0.25 → 0.5 → 1.0 → 2.0 mg SubQ weekly. Rybelsus (oral): 3 → 7 → 14 mg daily.

Route

SubQ

SubQ or Oral

Frequency

Once daily

Once weekly (SubQ); once daily (oral)

Dosing Notes

No clinically validated dose exists for any human indication. Community/grey-market protocols typically use 250–500 mcg (commonly 300 mcg) SubQ once daily, often in the morning fasted, for 8–12 week cycles. These protocols are extrapolated from abandoned clinical development doses and are not supported by positive efficacy data.

Per FDA labels, SubQ doses are escalated every 4 weeks to minimize GI adverse effects; 0.25 mg is a starting dose only and is not effective for maintenance. Rybelsus must be taken in the morning on an empty stomach with up to 4 oz (120 mL) of plain water, then no food, drink, or other oral medications for at least 30 minutes. Administer SubQ injections in the abdomen, thigh, or upper arm on the same day each week.

Side Effects

Injection site reactions — redness, soreness
Headache
Overall adverse-event rate in Phase 1/2 trials was indistinguishable from placebo
Long-term safety in chronic non-clinical use is unknown

Nausea, vomiting, diarrhea, or constipation (most common; usually dose-dependent and transient)
Abdominal pain and dyspepsia
Decreased appetite and early satiety; delayed gastric emptying
Injection site reactions (SubQ forms)
Acute pancreatitis (uncommon; discontinue if suspected)
Gallbladder disease (cholelithiasis, cholecystitis)
Acute kidney injury, often secondary to dehydration from GI losses
Hypoglycemia (primarily when combined with insulin or sulfonylureas)
Diabetic retinopathy complications in patients with preexisting retinopathy

Contraindications

Pregnancy and breastfeeding (no human data)
Known hypersensitivity to the peptide or excipients
Active malignancy (theoretical caution, extrapolated from GH-axis agents despite lack of IGF-1 effect)
Not established as effective for weight loss — GLP-1 receptor agonists have far stronger evidence

Personal or family history of medullary thyroid carcinoma (MTC) — FDA boxed warning based on rodent C-cell tumor findings
Multiple endocrine neoplasia syndrome type 2 (MEN 2) — FDA boxed warning
Prior serious hypersensitivity reaction to semaglutide or any product excipient
Caution (not absolute contraindication per label) with history of pancreatitis, severe gastroparesis, or diabetic retinopathy
Not recommended in pregnancy; discontinue at least 2 months before a planned pregnancy due to long half-life

AOD-9604 Research Summary

Preclinical: Ng et al. (Horm Res 2000) and Heffernan et al. (Int J Obes 2001; Endocrinology 2001) reported reduced body weight gain and increased fat oxidation in rodent models. Clinical: Six randomized, double-blind, placebo-controlled Phase 1/2 trials across ~900 subjects established a safety profile indistinguishable from placebo (Stier et al., J Endocrinol Metab 2013) but did NOT demonstrate clinically meaningful weight loss; a 24-week Phase 2b trial (~536 subjects) failed its primary efficacy endpoint and obesity development was terminated in 2007. Later preclinical work explored intra-articular use in a rabbit osteoarthritis model (Kwon & Park 2015); no adequately powered human OA trial has been published. Regulatory: AOD-9604 is NOT FDA-approved. It was placed on the FDA interim 503A Category 2 list (may present significant safety risk) in 2023, removed from Category 2 in September 2024 after the nominator withdrew, and at the December 4, 2024 PCAC meeting the committee voted AGAINST inclusion on the 503A Bulks List. Widely sold for 'weight loss' and osteoarthritis via grey-market and compounding channels without adequate human efficacy data.

Key references

Semaglutide Research Summary

The STEP program (STEP 1–8) showed average weight loss of roughly 15% of body weight over 68 weeks with weekly 2.4 mg semaglutide. The SUSTAIN program established A1c and cardiovascular benefit in type 2 diabetes. The PIONEER program established efficacy of oral semaglutide (Rybelsus) versus placebo, sitagliptin, empagliflozin, and liraglutide. The SELECT trial (2023) showed a 20% relative reduction in major adverse cardiovascular events in adults with overweight/obesity and established cardiovascular disease but without diabetes, leading to an expanded Wegovy indication.

Key references

Can you stack AOD-9604 and Semaglutide?

AOD-9604 and Semaglutide are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.

Other comparisons

BPC-157 vs TB-500 Semaglutide vs Tirzepatide Ipamorelin vs CJC-1295 CJC-1295 vs Sermorelin Semaglutide vs Liraglutide Selank vs Semax BPC-157 vs GHK-Cu MK-677 vs Ipamorelin

This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.

AOD-9604

Semaglutide

AOD-9604 Research Summary

Semaglutide Research Summary

Can you stack AOD-9604 and Semaglutide?